Compositions and methods for altering Wnt autocrine signaling
US8809287B2 · kind B2 · utility
11Cited by
24References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 15, 2005 |
| Grant date | Aug 19, 2014 |
| Priority date | — |
| Expiry date | Jul 25, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a compound that alters Wnt signaling. The compound that alters Wnt signaling can be a Wnt antagonist, a Wnt receptor antagonist, or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.